Radiopharmaceutical firm Cell>Point said findings from Phase I and IIa trials were promising for its technetium-99m-labeled ethylenedicysteine-glucosamine, an imaging agent used in diagnosing coronary artery disease. The company is planning a Phase IIb study to assess the diagnostic accuracy of the agent in identifying ischemia in patients at rest who have coronary artery disease.

Related Summaries